| Detailed information |
|---|
| CancerLivER ID | 2044 |
| Biomarker | lncBRM |
| Biomarker Name/Symbol (given in Publication) | lncBRM |
| Biomolecule | LncRNA |
| Subject | Human |
| Degree of Validity | lncBRM and YAP1 signalling may serve as biomarkers for diagnosis and potential drug targets for HCC and validated on different patients cohorts |
| Experimental Condition | Liver CSCs (Cancer stem cells) and early and advanced HCC tumours |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in HCC tumours and liver CSCs |
| Level of significance | p < 0.001 |
| Source | Tissue |
| PMID | 27905400 |
| Type of Biomarker | Diagnostic and Prognostic |
| Pathway | It is required for self-renewal and maintenance of liver CSCs |
| Cohort | HCC cell lines Huh7, Hep3B and various patients cohorts of PLC (GSE66529, GSE14520, GSE25097 and GSE54238) |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human HCC |
| Year of Publication | 2016 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |